Does the WT1 Plus Oncology Vaccine work on lumps?

Yes, the WT1 Plus tumor vaccine studied in Japan is not only suitable for prevention of high-risk groups, but also has an effect on cancer recovery**.

WT1 Plus tumor vaccine is suitable for patients with liver mass, kidney mass and other patients at risk of cancer, after injection of the vaccine, the lump shrinks and the tumor marker is reduced, so as to prevent the mass from becoming cancerous. Prevents 95% of cancers.

The WT1 Plus oncology vaccine has been approved by the Ministry of Health and Welfare of Japan and has been legally used for more than 10 years.

A representative method to annihilate the specificity of cancer cells** is the DC cell anti-tumor WT-1 vaccine**.

Dendritic cells are a type of immune cell that is the commander of the defense system in the body. Dendritic cells transfer the markers of cancer cells to T lymphocytes, which can exclude cancer cells, and effectively attack cancer cells. The most important point is what cancer antigen is used.

Prior to this, many cancer antigens were discovered, and the cancer antigen that has attracted much attention is "WT1". Wt1 gene (Wilm Tumor Gene1) is a tumor suppressor gene containing zinc finger-shaped polypeptide isolated from Wilms tumor cells. In 1899, Wilms gave a detailed pathological description of the disease.

In 2009, the National Cancer Institute (NCI) analyzed and compared 75 malignant tumor antigens, and WT1 stood out from the 75 artificial antigens and topped the list as "antigens with high priority for cancer antigens". WT1 is present in almost all types of cancer, and a subset of its "WT1 peptide" can be used for almost all cancers.

WT1, a gene that inhibits cancer

WT1 is expressed in leukemia and a variety of solid tumor tissues, and is one of the best tumor antigens found so far, and it induces the immune system to produce memory T cells that recognize cancer cells by inoculating more than 30 cancer antigens such as WT1. These memory T cells have a lifelong immune monitoring effect on the body and differentiate effector T cells to target cancer cells when they are found.

DC cell anti-tumor WT-1 vaccine.

Effective prevention of cancer, **cancer metastasis and **efficacy, away from the risk of disease.

The DC cell anti-tumor WT-1 vaccine is a prophylactic broad-spectrum tumor vaccine approved by the Ministry of Health and Welfare of Japan and produced by The Institution of Medical Oncology, Japan, which can effectively prevent more than 20 types of cancer. As of today, more than hundreds of thousands of patients have been vaccinated.

Huai Health provides DC cell anti-tumor WT-1 vaccine ordering consulting services.

**V day super poor parking lot hot wash this baby grab the doll this socks password card.

When the WT1 Plus tumor vaccine is injected near the lymph node, IL-2 attracts T cells to the injection point and activates T cells; GM-CSF chemizes the DC to the injection point, phagocytoses the treated antigen, and presents the antigen to the T cells to produce killer T cells and memory T cells against the cancer antigen, and once it encounters the cancer cells carrying the cancer antigen again, it will exert its cytotoxic effect and kill the cancer cells.

WT1 Plus tumor vaccine uses the original antigen expressed by the cell line, plus WT1, MCU1 and other broad-spectrum antigen peptides, which is effective against 95% of cancer recovery**. The vaccine has been approved for legal use by the Ministry of Health and Welfare of Japan.

When the WT1 Plus tumor vaccine is injected near the lymph node, IL-2 attracts T cells to the injection point and activates T cells; GM-CSF chemizes the DC to the injection point, phagocytoses the treated antigen, and presents the antigen to the T cells to produce killer T cells and memory T cells against the cancer antigen, and once it encounters the cancer cells carrying the cancer antigen again, it will exert its cytotoxic effect and kill the cancer cells.

WT1 Plus tumor vaccine can prevent 95% of cancers by using the original antigen expressed by the cell line, plus a broad spectrum of antigenic peptides such as WT1 and MCU1. It is also effective in cancer recovery**. The vaccine has been approved for legal use by the Ministry of Health and Welfare of Japan.